TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...

MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.